Publications
2 shownTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDI...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 1,043
- Institution
- Columbia University Irving Medical Center
External Links
Identifiers
- ORCID
- 0000-0002-9703-2265
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.